Roche China, Shanghai Pharma Defend Tamiflu After Report Challenges Efficacy
This article was originally published in PharmAsia News
Executive Summary
Roche China has strongly defended Tamiflu (oseltamivir) after the release of an analytical report from the non-profit Cochrane Collaboration that indicated that the efficacy is limited and side effects underrated based on a clinical trial of 9,623 people.